ARCHIVES

Did Iressa Data Merit Approval? Experts Discuss Implications For Drug Development, Lung Cancer Treatment, Reimbursement (12-page issue).

This article is from The Cancer Letter archive.

Vol. 29 No. 19 | May 9, 2003

Download PDF Visit The Full Archive

Related Articles

Analysis Reveals CAIX Subgroup Responsive to Rencarex Therapy

June 28, 2013

NCAB Considering Concept Review Of Large, Expensive Investigator Initiated Proposals

February 16, 1990

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

April 25, 2014

President Obama Visits NIH To Announce 12,000 Recovery Act Grants Worth $5 Billion

October 2, 2009

One Flexible Sigmoidoscopy Can Reduce Risk by 31 Percent

September 30, 2011

DCE director Adamson To Retire August 31

June 3, 1994